$Novavax(NVAX)$ Big Tech is expected to spend $700–725 billion on capex in 2026. Amazon around $200 billion, Microsoft around $190 billion, Google $180–190 billion, Meta $125–145 billion. That's up roughly 75% from $410 billion last year.
At this point it eats nearly all of their operating cash flow. Some of it is being funded with debt, which is new for that group.
Meanwhile, Novavax booked $125 million today.
Capex required: zero.
No data center. No fab. No factory. No Phase 3 budget. No sales force. No inventory.
Sanofi runs the trial. Sanofi funds the trial. Sanofi dosed patient number five in Europe, and Novavax got paid for it.
Roughly $0.76 per share, essentially cost-free. Around 165 million shares, by my arithmetic.
Still contracted and outstanding: $75 million on tech transfer, $225 million on the U.S. launch of the flu-COVID combination, up to $500 million from Pfizer for Matrix-M, and royalties on all of it.
The honest flip side, because a one-sided pitch is worthless: capital-light also means you don't own the economics. Sanofi keeps the margin, Novavax takes a royalty. Lower ceiling. But also far lower risk, and no depreciation schedule anyone has to guess at.
Everyone's arguing about whether six-year GPU useful lives are realistic.
Nobody has to guess what a milestone payment depreciates to.
Comments